Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Scil Proteins GmbH. (5/8/14). "Press Release: Scil Proteins Announces New Management Team and Revised Focus". Halle.

Organisations Organisation Scil Proteins GmbH
  Today Navigo Proteins GmbH
  Group UV-Cap (Group)
  Organisation 2 BioNet Ventures GmbH
  Group Coral BioNet (Group)
Products Product Affilin® therapeutic
  Product 2 contract manufacturing (biologicals)
  Index term 2 Coral BioNet–Wacker: investment, 201311– acquisition 100% of Scil Proteins Production GmbH by Wacker Biotech GmbH from BioNet Ventures GmbH
Persons Person Afflerbach, Henning (Coral BioNet 201205 CBO at Scil Proteins)
  Person 2 Haupts, Ulrich (Coral BioNet 201109– CSO of Scil Proteins GmbH before Bayer + Direvo Biotech + SKB UK)
     


Scil Proteins, the expert company in Affilin®-based protein engineering, today announced that Dr Henning Afflerbach has been appointed as chief executive officer (CEO) and Dr Ulrich Haupts is named managing director, in addition to his current role as chief scientific officer (CSO).

The new management team will focus on driving the commercialization of Scil Proteins' proprietary Affilin® platform. Core focus areas will be the development of drug conjugates and multi-specific protein binding molecules, as well as ligands for non-therapeutic applications, such as innovative diagnostics. The company is fully owned by BioNet Ventures GmbH. Early 2014, BioNet Ventures sold Scil Proteins' sister company and microbial manufacturing specialist Scil Proteins Production to Wacker Biotech GmbH. BioNet Ventures remains the only shareholder of Scil Proteins.

Dr Afflerbach commented: "I am excited about my new role as CEO of Scil Proteins and very much look forward to working closely with Dr Ulrich Haupts in continuing to support our biopharma and life sciences partners with the generation and optimization of unique Affilin®-based protein therapeutics, diagnostics and bioreagents."

Dr Ulrich Haupts added: "It is a pleasure working with Scil Proteins' outstanding team of highly motivated protein engineering specialists and leveraging our fully automated high-throughput screening, bioinformatics and assay development platforms to expand the applicability of our Affilin®-based biomolecules in areas where conventional approaches, including antibodies, have their limitations."

Prior to taking on his new role as CEO, Dr Afflerbach was responsible for leading business development and strategic planning for both Scil Proteins and Scil Proteins Production as chief business officer. He joined the Company in 2009 following various roles within Peptor GmbH/Ltd (Rehovot, Israel/Erkrath, Germany), Develogen AG (Göttingen, Germany) and DIREVO Biotech AG (Cologne, Germany).

Dr Haupts joined Scil Proteins as CSO in 2011 after more than 15 years of experience in both large pharma and biotech companies, including Bayer Healthcare AG (Cologne, Germany), DIREVO Biotech AG and SmithKline Beecham (Harlow, UK).

Affilin®-based biomolecules are derived from human scaffold proteins and have high stability, affinity and specificity making them ideal for a range of applications, including those where antibodies have limitations, thus broadening the potential of biotherapeutics.

- Ends -


About Scil Proteins

Scil Proteins is a private protein engineering company that is focused on generating and optimizing unique Affilin®-based proteins for therapeutic and non-therapeutic applications, such as innovative diagnostics, using its proprietary flexible and modular Affilin® platform for partners in the pharmaceutical, biotech and life science industries.

Affilin®-based molecules are derived from human scaffold proteins and have high stability, affinity and specificity, making them ideal for a range of applications that demand targeting and capturing of biomolecules. The unique properties of these Affilin®-based molecules are enabling them to overcome several of the limitations of antibodies, especially in specific niche applications.

The Company's core business areas include the development of drug conjugates and multi-specific protein binding molecules, as well as ligands for non-therapeutic applications. All of these core areas are underpinned by state-of-the-art protein engineering technologies and a team with an unrivalled depth of expertise and track record in this area, making Scil Proteins an attractive partner.

To learn more about Scil Proteins, please visit the company's new website: www.scilproteins.com


Contact

Scil Proteins GmbH
Henning Afflerbach
CEO
t: +49 (0) 345 2799 6365
e: Henning.Afflerbach@scilproteins.com

Instinctif Partners
Robert Mayer / Cora Kaiser
t: +49 (0)89 3090 5189 13 / 11
e: ScilProteins@Instinctif.com

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for UV-Cap (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top